---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-008585"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2022-06-21T23:59:59+00:00"
generated_at: "2026-06-25T00:27:30.362745+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zomedica acquires Revo Squared veterinary imaging assets for $6M cash plus earn-out and warrants

## Summary
- Base purchase price $6M cash, subject to working capital adjustments; $500K held in escrow for 15 months.
- Up to $4M in earn-out payments based on net sales milestones ($2M each for $5M and $10M threshold) through 2027.
- Warrants to purchase 10M common shares issued at closing; exercise price tied to ZOM closing price on closing date.
- Acquisition includes MicroView digital cytology platform, an automated slide preparation and imaging system for veterinary clinics.
- Closing expected on or around July 1, 2022; Revo Squared CEO Bill Campell and Senior Director Negin Ghassemian to join Zomedica.

## SEC filing metadata
- accession: 0001654954-22-008585
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2022-06-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495422008585/0001654954-22-008585-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495422008585/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-008585
- JSON: https://secwatch.observer/filing/0001654954-22-008585.json
- Plain text: https://secwatch.observer/filing/0001654954-22-008585.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.